Publications by authors named "Paula Bendet"

7Publications

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.

J Antimicrob Chemother 2020 02;75(2):392-399

Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkz460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966096PMC
February 2020

Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.

J Antimicrob Chemother 2019 07;74(7):1952-1961

Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkz143DOI Listing
July 2019

Once-a-week tigecycline for the treatment of drug-resistant TB.

J Antimicrob Chemother 2019 06;74(6):1607-1617

Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkz061DOI Listing
June 2019

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Clin Infect Dis 2018 11;67(suppl_3):S317-S326

Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/ciy609DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260165PMC
November 2018

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.

Antimicrob Agents Chemother 2018 02 25;62(2). Epub 2018 Jan 25.

Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA

View Article

Download full-text PDF

Source
http://aac.asm.org/lookup/doi/10.1128/AAC.02232-17
Publisher Site
http://dx.doi.org/10.1128/AAC.02232-17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786797PMC
February 2018